Navigation Links
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Date:8/19/2007

ram.

IND Filed with FDA to Enable Clinical Testing of New Oral Drug for Bone Disease

In August 2007, the Company filed an Investigational New Drug Exemption (IND) with the FDA's Division of Endocrinologic and Metabolic Drugs for a newly formulated compound, known as G4544. Developed out of a joint collaboration with Emisphere Technologies, Inc., G4544 is a new tablet formulation that enables oral absorption of the active ingredient contained in Ganite. This compound is a highly potent inhibitor of calcium release from bone. Diseases associated with accelerated bone loss include hypercalcemia, bone metastases, Paget's disease and osteoporosis. Genta currently intends to manage the clinical development process of oncology indications and to seek a development and commercial partner for non-malignant metabolic bone diseases. Assuming regulatory concurrence with the IND plan to establish bioequivalence with the FDA-approved parenteral product, Genta expects to initiate the initial clinical trial of G4544 in the second half of 2007.

Stock Trading and Capital Structure

In July, Genta was notified by NASDAQ that the Company has demonstrated compliance with all NASDAQ Marketplace rules. As a consequence, the NASDAQ Listings Qualifications Panel determined that Genta's common stock will continue to be listed on the NASDAQ Global Market. As part of the plan to establish compliance, Genta stockholders approved a one-for-six reverse split of the Company's shares of common stock, which reduced the number of outstanding shares to approximately 31 million. The Company's common stock temporarily trades under the symbol "GNTAD". On or about August 10, 2007, the Company expects that the common stock will resume trading under its former symbol, "GNTA".

Financial Information

All share and per share data included in this press release have been retroactively adjusted to account for the effect of the 1-for-6 reverse stock split on July 13, 2007. The Co
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 Dynatronics Corporation (the "Company") ... of rehabilitation and physical therapy products, announced today ... raise approximately $4,000,000 in a private placement financing ... its affiliates (together with its affiliates, "Prettybrook"), a ... industry. The financing will provide Dynatronics with additional ...
(Date:5/4/2015)... 4, 2015   Mallinckrodt plc (NYSE: MNK ... May 13, 2015, at the Bank of America Merrill Lynch ... in Las Vegas, Nev. ... Financial Officer, and Cole Lannum , Senior Vice President ... company in a session scheduled to begin at 3 p.m. ...
(Date:5/4/2015)... Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ), ... of proprietary compounded drug therapies, today reported that it ... Wednesday, May 13, 2015.  The company will host a ... on the same day to discuss its financial results ... and webcast will be open to all listeners and ...
Breaking Medicine Technology:Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 3Dynatronics Announces $4,000,000 Private Placement Led By Prettybrook Partners 4Mallinckrodt To Present At Bank Of America Merrill Lynch 2015 Health Care Conference 2Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 2Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT 3
... Scientific Corporation (NYSE: BSX ) today announced ... 60th Annual Scientific Session of the American College of ... "Twelve-month results from the PLATINUM Workhorse clinical trial ... Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to our ...
... DIEGO, March 29, 2011 Awarepoint Corporation announced ... at the First Annual Digital Healthcare Innovation Summit ... Intercontinental New York Barclay in New York. Joining Deady on ... of Dell Healthcare Services and Kaveh Safavi, M.D., vice president ...
Cached Medicine Technology:Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 2Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 3
(Date:5/4/2015)... For partners who’d like to become ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional ... levels, Astroglide TTC™ is specially formulated to provide a ... Centers for Disease Control, an average of one ... sustaining a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 ... just released the first-ever congenital heart disease ... Catheterization Laboratory (PCCL) accreditation. Driven by the ... are a comprehensive review of interventional procedures ... heart disease. , “The ACE CHD Standards ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Sara ... a physician practice management firm in Los Angeles associated ... today the patent-pending status of The Sara Soulati Health ... Soulati in 2010, is a lifestyle modification and disease ... April 2015 to the U. S. Patents and Trademarks ...
(Date:5/3/2015)... ANGELES, American Telemedicine Association 2015 Meeting & Tradeshow ... e-health solutions, a full-service telemedicine and mobile health ... new platform, VITA health services for chronic disease ... services platform enables remote patient monitoring of a ... heart failure (CHF), diabetes, COPD, hypertension and other ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 “ BolehVPN ” ... Report, which features the latest and coolest technology products available ... for NewsWatch, conducted the review and shared with viewers how ... everyone does these days is on computers and even more ... families and meet people all over the world. In terms ...
Breaking Medicine News(10 mins):Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2
... germ that caused the plague epidemic that ravaged medieval Europe ... form easier to treat//, according to a study published on ... both bubonic plague, the dreaded Black Death spread when people ... from one person to another through coughing or sneezing. ...
... has received a $3.5 million National Institute of Child ... research program// on autism and related developmental disorders. ... aspects and outcomes for affected patients. The project includes ... in infants at risk for the condition, and funds ...
... have found a new technique that employs RNA, a tiny ... to therapeutics// for conditions in which nudging a gene awake ... a novel research tool to investigate the role that genes ... appearing online at Nature Chemical Biology and in an upcoming ...
... by HealthGrades, a leading independent healthcare ratings company, patients ... better chance of surviving, on average, than those admitted ... have also found that the patients who undergo surgery ... lower risk of complications during their stay. ...
... Swedish researchers have found out that consuming the right type ... children are habituated to consume lesser quantities// of unsaturated fat ... healthy children in the age group of four was undertaken ... with good socio-economic background. ,This study revealed that ...
... Government has come down heavily on alternative therapists who ... are about one lakh therapists said to exist in ... tab on these professionals. On the other hand, completely ... Medical Council have strict rules and guidelines regarding their ...
Cached Medicine News:Health News:Scientists Find Potential Weakness In Plague Germ 2Health News:A Novel Technique Nudges Genes Into Activity 2Health News:A Novel Technique Nudges Genes Into Activity 3Health News:28% Lower Mortality Rate In Top U.S. Hospitals 2
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
Inquire...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
Medicine Products: